Havana, Nov 27.- BioWorld, a renowned North American pharmaceutical magazine, highlighted the achievements of Cuban science in the development of its second vaccine candidate against Covid-19, Soberana 02.
This was published on his official profile on Twitter by José Ramón Cabañas, ambassador of Havana in Washington, who also shares the link to the article in the publication, where reference is made to said vaccine candidate, who is currently going through phase I of clinical trials.
According to the text published in the last few hours, the Caribbean nation has a lot of experience in the formulation of conjugate vaccines, a group to which this drug belongs, the Prensa Latina agency cites.
"Evidence of this is the injectable QUIMI-HIB against Haemophilus Influenzae type B, which causes meningitis and pneumonia in the first years of life," the text refers.
This Thursday, the Regulatory Authority for Medicines, Equipment and Medical Devices of the Republic of Cuba (CECMED), also authorized the start of clinical trials of vaccine candidates against Covid-19 Mambisa and Abdala.
According to a message posted on the social network Twitter by the Business Group of the Biotechnology and Pharmaceutical Industries of Cuba (BioCubaFarma), with this authorization the country already has four vaccine candidates in the testing phase. (ACN) (Photo: File)